...
首页> 外文期刊>Acta biomaterialia >Development and in vivo safety assessment of tenofovir-loaded nanoparticles-in-film as a novel vaginal microbicide delivery system
【24h】

Development and in vivo safety assessment of tenofovir-loaded nanoparticles-in-film as a novel vaginal microbicide delivery system

机译:载有替诺福韦的纳米微粒薄膜作为新型阴道杀菌剂递送系统的开发和体内安全性评估

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Topical pre-exposure prophylaxis (PrEP) with antiretroviral drugs holds promise in preventing vaginal transmission of HIV. However, significant biomedical and social issues found in multiple past clinical trials still need to be addressed in order to optimize protection and users' adherence. One approach may be the development of improved micobicide products. A novel delivery platform comprising drug-loaded nanoparticles (NPs) incorporated into a thin polymeric film base (NPs-in-film) was developed in order to allow the vaginal administration of the microbicide drug candidate tenofovir. The system was optimized for relevant physicochemical features and characterized for biological properties, namely cytotoxicity and safety in a mouse model. Tenofovir-loaded poly(lactic-co-glycolic acid) (PLGA)/stearylamine (SA) composite NPs with mean diameter of 127 nm were obtained with drug association efficiency above 50%, and further incorporated into an approximately 115 mu m thick, hydroxypropyl methylcellulose/poly (vinyl alcohol)-based film. The system was shown to possess suitable mechanical properties for vaginal administration and to quickly disintegrate in approximately 9 min upon contact with a simulated vaginal fluid (SVF). The original osmolarity and pH of SVF was not affected by the film. Tenofovir was also released in a biphasic fashion (around 30% of the drug in 15 min, followed by sustained release up to 24 h). The incorporation of NPs further improved the adhesive potential of the film to ex vivo pig vaginal mucosa. Cytotoxicity of NPs and film was significantly increased by the incorporation of SA, but remained at levels considered tolerable for vaginal delivery of tenofovir. Moreover, histological analysis of genital tissues and cytokine/chemokine levels in vaginal lavages upon 14 days of daily vaginal administration to mice confirmed that tenofovir-loaded NPs-in-film was safe and did not induce any apparent histological changes or pro-inflammatory response. Overall, obtained data support that the proposed delivery system combining the use of polymeric NPs and a film base may constitute an exciting alternative for the vaginal administration of microbicide drugs in the context of topical PrEP.
机译:抗逆转录病毒药物的局部暴露前预防(PrEP)在预防HIV的阴道传播方面有希望。但是,仍需要解决在过去的多个临床试验中发现的重大生物医学和社会问题,以优化保护和用户依从性。一种方法可能是开发改良的杀微生物产品。为了允许阴道杀菌剂候选替诺福韦的阴道给药,开发了一种新型的递送平台,该平台包括掺入聚合物薄膜基质(薄膜中的NPs)中的载有药物的纳米颗粒(NPs)。该系统针对相关的理化特性进行了优化,并针对生物学特性(即小鼠模型中的细胞毒性和安全性)进行了表征。获得了载有替诺福韦的聚乳酸-乙醇酸(PLGA)/硬脂胺(SA)复合纳米颗粒,平均直径为127 nm,药物缔合效率超过50%,并进一步掺入约115μm厚的羟丙基甲基纤维素/聚乙烯醇薄膜。该系统显示具有适合阴道给药的机械性能,并且在与模拟阴道液(SVF)接触后约9分钟内迅速崩解。 SVF的原始渗透压和pH值不受膜的影响。替诺福韦也以双相方式释放(在15分钟内释放约30%的药物,然后持续释放直至24小时)。 NP的掺入进一步提高了膜对离体猪阴道粘膜的粘附潜力。掺入SA可以显着增加NP和薄膜的细胞毒性,但仍保持替诺福韦经阴道给药可耐受的水平。此外,对小鼠每天阴道给药14天后,对阴道灌洗液中生殖器组织和细胞因子/趋化因子水平的组织学分析证实,载有替诺福韦的NPs涂膜是安全的,不会引起任何明显的组织学改变或促炎反应。总体而言,获得的数据支持,在局部使用PrEP的情况下,拟议的递送系统结合了聚合物NP和薄膜基质的使用,可能构成阴道杀菌剂药物的激动人心的替代选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号